Collaborations

Agreement signed with Prostagenics to develop prostate cancer treatment

Published in Cancer Weekly, May 10th, 2005

Innovate Oncology, Inc., (IOVO), a company founded by Bioaccelerate Holdings, Inc., (BACL), announced that it has entered into an exclusive agreement with Prostagenics LLC, acquiring the rights to develop and commercialize Capridine-Beta for the treatment of prostate cancer.

Capridine-Beta is a novel nitroacridine derivative, which has shown specific activity against prostate cancer. It works by stimulating expression of p16, the tumor-suppressor gene and inhibits cyclic dependent kinases CDK-2, CDK-4 and CDK-6. Capridine-Beta also renders aggressive hormone-independent prostate cells hormone-sensitive.

Therefore, Capridine-Beta may be effective in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-05-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry